Sensorion to begin Phase II clinical trial of SENS-111 to treat vertigo

French biotech company Sensorion is set to begin its Phase II clinical trial of SENS-111 to treat acute severe vertigo.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news